Trading Update
1 October 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Trading Update
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces an update on its trading for the six months ending 30 September 2024.
Aivlosin® continues to gain market share in key territories, particularly Brazil and India, with revenues in these regions exceeding the Board's expectations. In addition, and as expected, we are continuing to gain market share in the US. We are however, encountering challenges in China, due to low disease incidence in the summer months, and in Southeast Asia, where sales have slowed reflecting some customer churn.
The ECO Group is second half weighted and this pattern will continue in FY 2025. Nevertheless, the recent challenges we've faced in China and Southeast Asia lead us to believe that revenue for the full year will be materially below market expectations.1
Due to the complex mix of geographies in which the ECO Group operates, foreign exchange headwinds, and the differing gross margins across each region, forecasting an adjusted EBITDA figure for the full year at this stage is challenging. The Board expects that adjusted EBITDA for FY25 will be in the region of that observed in FY23 and notes it is likely that more accurate guidance will be provided when interim results to 30 September 2024 are announced in late November.2
The ECO Group has grounds for optimism for an improved performance in the second half with pork prices improving in China, strong order books and continuing strength in North America, Brazil and India. In addition, we have recently been notified that the ECO Group has received regulatory approval for the marketing of Aivlosin® in Paraguay. This market produced 1.4m pigs in 2023, nearly 80% of which were in industrial farms.
The ECO Group is strongly cash generative and has a non-China cash balance in-line with that on hand at 31 March 2024. This ensures that the ECO Group's valuable R&D programme continues to move forward on a self-funded basis at the planned rate.
1. The Board understands market expectations for revenue and EBITDA in FY25 is £92.6m and £8.2m respectively.
2. Reported audited revenue and adj EBITDA for FY23 was £85.3m and £7.2m respectively.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 29 minutes ago Alphawave IP Group
- 1 hour ago WH Smith
- 1 hour ago Staffline Group
- 2 hours ago Manchester & London Investment Trust
- 2 hours ago Associated British Foods